Selective Interleukin-6 Trans-Signaling Blockade Is More Effective Than Panantagonism in Reperfused Myocardial Infarction

被引：37
作者：
George, Marc Jonathan [1 ,2 ]
Jasmin, Nur Hayati [3 ]
Cummings, Valerie Taylor [3 ]
Richard-Loendt, Angela [4 ,5 ]
Launchbury, Francesca [5 ]
Woollard, Kevin [6 ]
Turner-Stokes, Tabitha [6 ]
Diaz, Ana Isabel Garcia [6 ]
Lythgoe, Mark [3 ]
Stuckey, Daniel James [3 ]
Hingorani, Aroon Dinesh [2 ,7 ]
Gilroy, Derek William [1 ]
机构：
[1] UCL, Dept Clin Pharmacol, Div Med, London, England
[2] Univ Coll London Hosp NHS Fdn Trust, Dept Clin Pharmacol, London, England
[3] UCL, Ctr Adv Biomed Imaging CABI, Div Med, London, England
[4] Univ Coll London Hosp NHS Fdn Trust, Dept Neuropathol, London, England
[5] UCL, Inst Neurol, UCL IQPath, London, England
[6] Imperial Coll London, Fac Med Immunol & Inflammat, London, England
[7] UCL, Inst Cardiovasc Sci, Ctr Translat Genom, London, England
来源：
JACC-BASIC TO TRANSLATIONAL SCIENCE | 2021年 / 6卷 / 05期
基金：
英国医学研究理事会; 英国惠康基金;
关键词：
inflammation; interleukin-6; myocardial infarction; reperfusion; IL-6; RECEPTOR; INJURY; INDUCTION; FIBROSIS; NECROSIS; HEART;
D O I：
10.1016/j.jacbts.2021.01.013
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Interleukin (IL)-6 is an emerging therapeutic target in myocardial infarction (MI). IL-6 has 2 distinct signaling pathways: trans-signaling, which mediates inflammation, and classic signaling, which also has anti-inflammatoryeffects. The novel recombinant fusion protein sgp130Fc achieves exclusive trans-signaling blockade, whereas anti-IL-6 antibodies (Abs) result in panantagonism. In a rat model of reperfused MI, sgp130Fc, but not anti-IL-6-Ab, attenuated neutrophil and macrophage infiltration into the myocardium, reduced infarct size, and preserved cardiac function 28 days after MI. These data demonstrate the efficacy of exclusive IL-6 trans-signaling blockade and support further investigation of sgp130Fc as a potential novel therapy in MI. (C) 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
引用
收藏
页码：431 / 443
页数：13
相关论文
共 32 条
  • [11] Novel Insights Into the Effects of Interleukin 6 Antagonism in Non-ST-SegmentElevation Myocardial Infarction Employing the SOMAscan Proteomics Platform
    George, Marc J.
    Kleveland, Ola
    Garcia-Hernandez, Jorge
    Palmen, Jutta
    Lovering, Ruth
    Wiseth, Rune
    Aukrust, Pal
    Engmann, Jorgen
    Damas, Jan Kristian
    Hingorani, Aroon D.
    Gullestad, Lars
    Casas, Juan P.
    Ueland, Thor
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (12):
  • [12] Inhibition of Interleukin-6 Receptor in a Murine Model of Myocardial Ischemia-Reperfusion
    Hartman, Minke H. T.
    Vreeswijk-Baudoin, Inge
    Groot, Hilde E.
    van de Kolk, Kees W. A.
    de Boer, Rudolf A.
    Leach, Irene Mateo
    Vliegenthart, Rozemarijn
    Sillje, Herman H. W.
    van der Harst, Pim
    [J]. PLOS ONE, 2016, 11 (12):
  • [13] Role of Lymphocytes in Myocardial Injury, Healing, and Remodeling After Myocardial Infarction
    Hofmann, Ulrich
    Frantz, Stefan
    [J]. CIRCULATION RESEARCH, 2015, 116 (02) : 354 - 367
  • [14] Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses
    Jostock, T
    Müllberg, J
    Özbek, S
    Atreya, R
    Blinn, G
    Voltz, N
    Fischer, M
    Neurath, MF
    Rose-John, S
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 2001, 268 (01): : 160 - 167
  • [15] Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction
    Kleveland, Ola
    Ueland, Thor
    Kunszt, Gabor
    Bratlie, Marte
    Yndestad, Arne
    Broch, Kaspar
    Holte, Espen
    Ryan, Liv
    Amundsen, Brage H.
    Bendz, Bjorn
    Aakhus, Svend
    Espevik, Terje
    Halvorsen, Bente
    Mollnes, Tom E.
    Wiseth, Rune
    Gullestad, Lars
    Aukrust, Pal
    Damas, Jan Kristian
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 271 : 1 - 7
  • [16] Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-STelevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial+
    Kleveland, Ola
    Kunszt, Gabor
    Bratlie, Marte
    Ueland, Thor
    Broch, Kaspar
    Holte, Espen
    Michelsen, Annika E.
    Bendz, Bjorn
    Amundsen, Brage H.
    Espevik, Terje
    Aakhus, Svend
    Damas, Jan Kristian
    Aukrust, Pal
    Wiseth, Rune
    Gullestad, Lars
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 (30) : 2406 - 2413
  • [17] Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice
    Kobara, Miyuki
    Noda, Kazuki
    Kitamura, Miho
    Okamoto, Akiharu
    Shiraishi, Tatsuya
    Toba, Hiroe
    Matsubara, Hiroaki
    Nakata, Tetsuo
    [J]. CARDIOVASCULAR RESEARCH, 2010, 87 (03) : 424 - 430
  • [18] Release Kinetics of Inflammatory Biomarkers in a Clinical Model of Acute Myocardial Infarction
    Liebetrau, Christoph
    Hoffmann, Jedrzej
    Doerr, Oliver
    Gaede, Luise
    Blumenstein, Johannes
    Biermann, Hannes
    Pyttel, Lukas
    Thiele, Peter
    Troidl, Christian
    Berkowitsch, Alexander
    Rolf, Andreas
    Voss, Sandra
    Hamm, Christian W.
    Nef, Holger
    Moellmann, Helge
    [J]. CIRCULATION RESEARCH, 2015, 116 (05) : 867 - 875
  • [19] Interleukin 6 Mediates Myocardial Fibrosis, Concentric Hypertrophy, and Diastolic Dysfunction in Rats
    Melendez, Giselle C.
    McLarty, Jennifer L.
    Levick, Scott P.
    Du, Yan
    Janicki, Joseph S.
    Brower, Gregory L.
    [J]. HYPERTENSION, 2010, 56 (02) : 225 - 231
  • [20] Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha
    Modur, V
    Li, YJ
    Zimmerman, GA
    Prescott, SM
    McIntyre, TM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11) : 2752 - 2756
1234